Scopus BioPharma Inc. (SCPS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Scopus BioPharma Inc. (SCPS) trades at $0.0004. Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology gene therapies and other therapeutics targeting serious diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for SCPS: SCPS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SCPS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SCPS.
How is this calculated? →Scopus BioPharma Inc. (SCPS) Healthcare & Pipeline Overview
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company developing immuno-oncology gene therapies and other therapeutics for serious diseases, leveraging its Duet Platform and MRI-1867, while forging strategic partnerships to advance its pipeline in the competitive biotechnology sector.
What Is the Investment Thesis for SCPS?
Scopus BioPharma Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on immuno-oncology gene therapy, particularly its Duet Platform and MRI-1867, offers potential for significant breakthroughs in cancer treatment. However, as a clinical-stage company with a market capitalization of $0.00 billion, Scopus BioPharma faces substantial challenges in navigating the regulatory approval process and securing funding for ongoing research and development. Key value drivers include the successful progression of its lead programs through clinical trials and the establishment of additional strategic partnerships. Upcoming catalysts include the release of clinical trial data and potential FDA approvals. Potential risks include clinical trial failures, regulatory setbacks, and the need for additional capital raising, which could dilute existing shareholders.
Based on FMP financials and quantitative analysis
SCPS Key Highlights
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing transformational therapeutics targeting serious diseases.
- The company's lead development programs are in immuno-oncology gene therapy for the treatment of various cancers.
- Scopus BioPharma offers the Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors.
- MRI-1867 is a rationally designed, orally available, dual-action, hybrid, and small molecule.
- The company has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem.
Who Are SCPS's Competitors?
SCPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCPS's Key Strengths?
Innovative technology platforms (Duet Platform, MRI-1867).
- Strategic partnerships with leading research institutions.
- Focus on high-growth immuno-oncology market.
- Experienced management team.
What Are SCPS's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources.
- High dependence on strategic partnerships.
- OTC market listing.
What Could Drive SCPS Stock Higher?
Release of clinical trial data for Duet Platform-based therapeutics.
- Regulatory submissions for MRI-1867.
- Expansion of strategic partnerships with research institutions and pharmaceutical companies.
- Advancement of immuno-oncology pipeline through internal research and development.
- Pursuit of orphan drug designations for therapeutic candidates.
What Are the Key Risks for SCPS?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $24.0M recently.
- Clinical trial failures for its therapeutic candidates.
- Regulatory setbacks and delays in obtaining approvals.
- Competition from established pharmaceutical companies and other biotech firms.
- Need for additional capital raising, which could dilute existing shareholders.
- Intellectual property disputes and patent challenges.
What Are the Growth Opportunities for SCPS?
- Advancement of Duet Platform: The Duet Platform, featuring CpG signal transducer and activator of transcription 3 (STAT3) inhibitors, represents a significant growth opportunity for Scopus BioPharma. Successful clinical trials and regulatory approvals for Duet Platform-based therapeutics could generate substantial revenue for Scopus BioPharma.
- Development of MRI-1867: MRI-1867, a rationally designed, orally available, dual-action molecule, offers another promising growth avenue for Scopus BioPharma. As an inverse agonist of the endocannabinoid system/cannabinoid receptor 1 and an inhibitor of inducible nitric oxide synthase, MRI-1867 has the potential to address a range of diseases, including inflammatory and neurological disorders. The market for such therapies is substantial, and successful development and commercialization of MRI-1867 could significantly boost Scopus BioPharma's revenue.
- Strategic Partnerships: Scopus BioPharma's strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem provide access to cutting-edge research and development capabilities. These partnerships can accelerate the development of new therapeutic programs and expand the company's pipeline. Further collaborations with leading research institutions and pharmaceutical companies could unlock additional growth opportunities for Scopus BioPharma.
- Expansion of Immuno-Oncology Pipeline: The company's focus on immuno-oncology gene therapy positions it within a high-growth segment of the biotechnology market. Scopus BioPharma can capitalize on this trend by expanding its immuno-oncology pipeline through internal research and development and strategic acquisitions.
- Orphan Drug Designations: Pursuing orphan drug designations for its therapeutic candidates represents a strategic growth opportunity for Scopus BioPharma. Orphan drug designation provides several benefits, including market exclusivity, tax credits, and reduced regulatory fees. These incentives can accelerate the development and commercialization of therapies for rare diseases, creating a competitive advantage for Scopus BioPharma.
What Are SCPS's Competitive Advantages?
- Proprietary technology platforms (Duet Platform, MRI-1867).
- Strategic partnerships with leading research institutions.
- Intellectual property protection (patents and trademarks).
What Does SCPS Do?
Scopus BioPharma Inc., established in 2017 and headquartered in New York City, is a clinical-stage biopharmaceutical company dedicated to creating transformational therapeutics for serious diseases, particularly in the realm of immuno-oncology. The company's lead development programs are centered around immuno-oncology gene therapy for the treatment of various cancers. Scopus BioPharma's portfolio includes the Duet Platform, which features CpG signal transducer and activator of transcription 3 (STAT3) inhibitors, and MRI-1867, a rationally designed, orally available, dual-action, hybrid, and small molecule that acts as an inverse agonist of the endocannabinoid system/cannabinoid receptor 1 and an inhibitor of inducible nitric oxide synthase. These innovative approaches reflect Scopus BioPharma's commitment to addressing unmet medical needs through cutting-edge research and development. The company has established strategic partnerships with renowned institutions such as the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem to bolster its research and development efforts and accelerate the advancement of its therapeutic programs. Formerly known as Project18 Inc., Scopus BioPharma Inc. is focused on translating scientific discoveries into effective therapies that can improve patient outcomes.
What Products and Services Does SCPS Offer?
- Develop immuno-oncology gene therapies for cancer treatment.
- Offer the Duet Platform, featuring CpG signal transducer and activator of transcription 3 (STAT3) inhibitors.
- Develop MRI-1867, a dual-action molecule targeting the endocannabinoid system and inducible nitric oxide synthase.
- Engage in strategic partnerships with research institutions.
- Conduct clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
- Seek regulatory approvals for its therapies from agencies like the FDA.
- Focus on transformational therapeutics for serious diseases.
How Does SCPS Make Money?
- Develop and patent novel therapeutic candidates.
- Out-license or co-develop its therapeutic candidates with larger pharmaceutical companies.
- Generate revenue through milestone payments and royalties from partnered programs.
What Industry Does SCPS Operate In?
Scopus BioPharma Inc. operates within the highly competitive biotechnology industry, which is characterized by rapid innovation, intense research and development, and stringent regulatory requirements. Scopus BioPharma's focus on immuno-oncology gene therapy positions it within a high-growth segment of the market, but it faces competition from established pharmaceutical companies and other emerging biotech firms. The company's success will depend on its ability to differentiate its therapeutic programs, secure regulatory approvals, and establish strategic partnerships to expand its market reach.
Who Are SCPS's Key Customers?
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients suffering from cancers and other serious diseases.
- Research institutions and hospitals.
Insider Activity
The most recent 11 insider filings for Scopus BioPharma Inc. break down as 3 sales and 8 purchases. On net that is roughly 6.0M shares disposed (about $24.0M), a signal worth weighing alongside the fundamentals.
Financial Health
Scopus BioPharma Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Scopus BioPharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Alan D. Horsager. SCPS has traded publicly since 2020.
SCPS Financials
Bull Case vs Bear Case
Bull Case
- Community sentiment has been increasingly positive, driven by recent advancements in their drug development.
- The company's focus on innovative therapies aligns with growing market interest in biopharmaceuticals.
- Recent partnerships and collaborations have strengthened their market position and expanded research capabilities.
Bear Case
- Concerns about the competitive landscape in the biopharma sector may impact market perception negatively.
- Recent news regarding regulatory hurdles could create uncertainty around their product approvals.
- Investor sentiment has shown caution due to the company's historical volatility and past performance.
- Market analysts have expressed skepticism about the scalability of their current projects, raising red flags for potential investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SCPS Latest News
No recent news available for SCPS.
SCPS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SCPS.
Price Targets
Wall Street price target analysis for SCPS.
SCPS MoonshotScore
What does this score mean?
The MoonshotScore rates SCPS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alan D. Horsager
CEO
Alan D. Horsager serves as the CEO of Scopus BioPharma Inc., managing a team of 13 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. He has held various executive positions at both public and private companies, contributing to the advancement of innovative therapies. Horsager's expertise spans areas such as drug development, clinical trials, and commercialization strategies.
Track Record: Under Alan D. Horsager's leadership, Scopus BioPharma Inc. has focused on advancing its lead development programs in immuno-oncology gene therapy and establishing strategic partnerships with renowned research institutions. Key milestones include the development of the Duet Platform and MRI-1867, as well as collaborations with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Horsager's strategic decisions have been instrumental in shaping the company's direction and driving its growth.
SCPS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Scopus BioPharma Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, potentially increasing investment risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited liquidity and trading volume.
- Lack of regulatory oversight and financial transparency.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Difficulty in obtaining accurate and reliable information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and funding needs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Strategic partnerships with reputable research institutions.
- Focus on innovative therapeutic programs.
- Experienced management team with industry expertise.
- Intellectual property protection (patents and trademarks).
- Active engagement with investors and stakeholders.
Scopus BioPharma Inc. Healthcare Stock: Key Questions Answered
What does Scopus BioPharma Inc. do?
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing transformational therapeutics targeting serious diseases, particularly in the field of immuno-oncology. The company's lead development programs include the Duet Platform, featuring CpG signal transducer and activator of transcription 3 (STAT3) inhibitors, and MRI-1867, a dual-action molecule targeting the endocannabinoid system and inducible nitric oxide synthase.
What do analysts say about SCPS stock?
As of 2026-03-16, there is no readily available analyst consensus on Scopus BioPharma Inc. (SCPS) due to its OTC listing and limited market capitalization. Investors should conduct their own independent research and consider the company's clinical-stage status, financial resources, and competitive landscape before making any investment decisions. Key valuation metrics are not applicable given the company's current financial performance.
What are the main risks for SCPS?
The main risks for Scopus BioPharma Inc. include clinical trial failures, regulatory setbacks, competition from established pharmaceutical companies, and the need for additional capital raising. As a clinical-stage company, Scopus BioPharma faces significant uncertainty in the development and approval of its therapeutic candidates. The company's limited financial resources and reliance on strategic partnerships also pose risks to its long-term viability.
How does Scopus BioPharma Inc. manage patent expiration risks?
As a clinical-stage biopharmaceutical company, Scopus BioPharma Inc. proactively manages patent expiration risks by strategically building a robust intellectual property portfolio around its key therapeutic candidates and technology platforms. This includes securing patents for novel compounds, formulations, and methods of use.
What is Scopus BioPharma Inc.'s drug pipeline status?
Scopus BioPharma Inc.'s drug pipeline is focused on immuno-oncology gene therapy and includes the Duet Platform and MRI-1867. The Duet Platform, featuring CpG signal transducer and activator of transcription 3 (STAT3) inhibitors, is in preclinical development for various cancers. MRI-1867, a dual-action molecule, is also in preclinical development for inflammatory and neurological disorders.
What are the key factors to evaluate for SCPS?
Evaluate SCPS on fundamentals, analyst consensus, and risk factors. Scopus BioPharma Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does SCPS data refresh on this page?
SCPS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SCPS's recent stock price performance?
Scopus BioPharma Inc. (SCPS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platforms (Duet Platform, MRI-1867). See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights.